These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8471696)

  • 21. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine.
    Gilmor ML; Owens MJ; Nemeroff CB
    Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression.
    Mück-Seler D; Pivac N; Sagud M; Jakovljević M; Mihaljević-Peles A
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1235-43. PubMed ID: 12502009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.
    Gleiter CH; Nilsson E; Mühlbauer B; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1992; 89(1-2):129-33. PubMed ID: 1418864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inhibition of monoamine oxidase by brofaromine.
    Anderson MC; Waldmeier PC; Tipton KF
    Biochem Pharmacol; 1991 Jun; 41(12):1871-7. PubMed ID: 2039542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
    Möller HJ; Wendt G; Waldmeier P
    Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments.
    Cheetham SC; Viggers JA; Slater NA; Heal DJ; Buckett WR
    Neuropharmacology; 1993 Aug; 32(8):737-43. PubMed ID: 8413837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography.
    Fritze J; Becker T; Ziegler V; Laux G; Bieck P; Sofic E; Riederer P
    J Neural Transm Suppl; 1990; 32():197-201. PubMed ID: 2089091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs.
    Blier P; Bouchard C
    Br J Pharmacol; 1994 Oct; 113(2):485-95. PubMed ID: 7834200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels.
    Griebel G; Curet O; Perrault G; Sanger DJ
    Neuropharmacology; 1998 Jul; 37(7):927-35. PubMed ID: 9776388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake.
    Marley E; Wozniak KM
    J Psychiatr Res; 1984; 18(2):173-89. PubMed ID: 6747915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
    Bakish D; Cavazzoni P; Chudzik J; Ravindran A; Hrdina PD
    Biol Psychiatry; 1997 Jan; 41(2):184-90. PubMed ID: 9018388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ; Yu PH
    Psychopharmacology (Berl); 1989; 98(2):265-8. PubMed ID: 2502797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine.
    Alvarez JC; Gluck N; Arnulf I; Quintin P; Leboyer M; Pecquery R; Launay JM; Perez-Diaz F; Spreux-Varoquaux O
    Clin Pharmacol Ther; 1999 Dec; 66(6):617-24. PubMed ID: 10613618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brofaromine in endogenous depression.
    Verhoeven WM
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):235-41. PubMed ID: 8208975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).
    Hyttel J
    Int Clin Psychopharmacol; 1994 Mar; 9 Suppl 1():19-26. PubMed ID: 8021435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.